相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial
Javier Martin-Broto et al.
JAMA ONCOLOGY (2020)
Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer
Dongyun He et al.
MEDICAL SCIENCE MONITOR (2020)
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype
Javier Martin-Broto et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
David S. Moura et al.
CANCERS (2020)
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets
Kristen E. Mengwasser et al.
MOLECULAR CELL (2019)
The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability
Emanuela Tumini et al.
MOLECULAR CANCER RESEARCH (2019)
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
Alessandro Gronchi et al.
ECLINICALMEDICINE (2019)
APE2 promotes DNA damage response pathway from a single-strand break
Yunfeng Lin et al.
NUCLEIC ACIDS RESEARCH (2018)
Developmental profiling of microRNAs in the human embryonic inner ear
Duncan M. Chadly et al.
PLOS ONE (2018)
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
Giovanni Grignani et al.
LANCET ONCOLOGY (2018)
Direct screening of plasma circulating microRNAs
Paola Songia et al.
RNA BIOLOGY (2018)
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D. Lorusso et al.
ANNALS OF ONCOLOGY (2016)
Unique features of trabectedin mechanism of action
Annette K. Larsen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples
Zhenhao Qi et al.
BIOANALYSIS (2016)
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
A. Laroche-Clary et al.
BRITISH JOURNAL OF CANCER (2015)
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review
Sheetal Sharma et al.
BMC CANCER (2013)
Identification of Poly(ADP-Ribose) Polymerase-1 as a Cell Cycle Regulator through Modulating Sp1 Mediated Transcription in Human Hepatoma Cells
Liu Yang et al.
PLOS ONE (2013)
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
Bartomeu Massuti et al.
LUNG CANCER (2012)
ERCC5/XPG, ERCC1, and BRCA1 Gene Status and Clinical Benefit of Trabectedin in Patients With Soft Tissue Sarcoma
Antoine Italiano et al.
CANCER (2011)
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study
P. Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2011)
Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action
Jordi Martinez-Serra et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Apurinic/Apyrimidinic Endonuclease 2 Is Necessary for Normal B Cell Development and Recovery of Lymphoid Progenitors after Chemotherapeutic Challenge
Jeroen E. J. Guikema et al.
JOURNAL OF IMMUNOLOGY (2011)
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
Christian Boehler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells
Giovanni Germano et al.
CANCER RESEARCH (2010)
A scaling normalization method for differential expression analysis of RNA-seq data
Mark D. Robinson et al.
GENOME BIOLOGY (2010)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
In vitro radiosensitisation by trabectedin in human cancer cell lines
Jesus Romero et al.
EUROPEAN JOURNAL OF CANCER (2008)
Poly(ADP-ribosyl)ation is implicated in the G0-G1 transition of resting cells
M. Carbone et al.
ONCOGENE (2008)
Small-sample estimation of negative binomial dispersion, with applications to SAGE data
Mark D. Robinson et al.
BIOSTATISTICS (2008)
PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery
M. Rouleau et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Anti-inflammatory properties of the novel antitumor agent yondelis (Trabectedin): Inhibition of macrophage differentiation and cytokine production
P Allavena et al.
CANCER RESEARCH (2005)
PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase
CM Simbulan-Rosenthal et al.
ONCOGENE (2003)
PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression
A Augustin et al.
JOURNAL OF CELL SCIENCE (2003)
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
Y Takebayashi et al.
NATURE MEDICINE (2001)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
M Minuzzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)